Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
- PMID: 20124171
- PMCID: PMC4872305
- DOI: 10.1200/JCO.2009.25.7246
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
Abstract
Purpose: The clinical efficacy of tamoxifen is suspected to be influenced by the activity of drug-metabolizing enzymes and transporters involved in the formation, metabolism, and elimination of its active forms. We investigated relationships of polymorphisms in transporter genes and CYP2D6 to clinical outcome of patients receiving tamoxifen.
Patients and methods: We studied 282 patients with hormone receptor-positive, invasive breast cancer receiving tamoxifen monotherapy, including 67 patients who have been previously reported. We investigated the effects of allelic variants of CYP2D6 and haplotype-tagging single nucleotide polymorphisms (tag-SNPs) of ABCB1, ABCC2, and ABCG2 on recurrence-free survival using the Kaplan-Meier method and Cox regression analysis. Plasma concentrations of tamoxifen metabolites were measured in 98 patients receiving tamoxifen 20 mg/d.
Results: CYP2D6 variants were significantly associated with shorter recurrence-free survival (P = .000036; hazard ratio [HR] = 9.52; 95% CI, 2.79 to 32.45 in patients with two variant alleles v patients without variant alleles). Among 51 tag-SNPs in transporter genes, a significant association was found at rs3740065 in ABCC2 (P = .00017; HR = 10.64; 95% CI, 1.44 to 78.88 in patients with AA v GG genotypes). The number of risk alleles of CYP2D6 and ABCC2 showed cumulative effects on recurrence-free survival (P = .000000055). Patients carrying four risk alleles had 45.25-fold higher risk compared with patients with <or= one risk allele. CYP2D6 variants were associated with lower plasma levels of endoxifen and 4-hydroxytamoxifen (P = .0000043 and .00052), whereas no significant difference was found among ABCC2 genotype groups.
Conclusion: Our results suggest that polymorphisms in CYP2D6 and ABCC2 are important predictors for the prognosis of patients with breast cancer treated with tamoxifen.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
![Fig 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4872305/bin/zlj9990996860001.gif)
![Fig 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4872305/bin/zlj9990996860002.gif)
![Fig 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4872305/bin/zlj9990996860003.gif)
![Fig A1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4872305/bin/zlj9990996860004.gif)
Comment in
-
Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.J Clin Oncol. 2010 Mar 10;28(8):1273-5. doi: 10.1200/JCO.2009.26.7906. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124162 No abstract available.
-
ABCC2 and clinical outcome of tamoxifen therapy.J Clin Oncol. 2010 Sep 1;28(25):e448; author reply e449. doi: 10.1200/JCO.2010.29.6665. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625134 No abstract available.
Similar articles
-
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. PLoS One. 2013. PMID: 24098545 Free PMC article. Review.
-
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.Cancer Chemother Pharmacol. 2012 Jul;70(1):75-81. doi: 10.1007/s00280-012-1891-1. Epub 2012 May 24. Cancer Chemother Pharmacol. 2012. PMID: 22623212
-
The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.AAPS J. 2012 Mar;14(1):52-9. doi: 10.1208/s12248-011-9313-6. Epub 2011 Dec 20. AAPS J. 2012. PMID: 22183189 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Health Technol Assess. 2011. PMID: 21906462 Free PMC article. Review.
-
Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.Breast Cancer Res Treat. 2012 Jan;131(2):455-61. doi: 10.1007/s10549-011-1425-2. Epub 2011 Mar 25. Breast Cancer Res Treat. 2012. PMID: 21437611
Cited by
-
Transporter Genes and statin-induced Hepatotoxicity.Cardiovasc Drugs Ther. 2024 May 29. doi: 10.1007/s10557-024-07580-2. Online ahead of print. Cardiovasc Drugs Ther. 2024. PMID: 38809397
-
Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen.J Pers Med. 2023 Jan 31;13(2):272. doi: 10.3390/jpm13020272. J Pers Med. 2023. PMID: 36836506 Free PMC article.
-
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28. Acta Pharm Sin B. 2023. PMID: 36815037 Free PMC article. Review.
-
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Clin Pharmacokinet. 2022 Nov;61(11):1495-1517. doi: 10.1007/s40262-022-01174-7. Epub 2022 Sep 30. Clin Pharmacokinet. 2022. PMID: 36180817 Review.
-
Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis.Expert Rev Mol Med. 2022 Jan 7;24:e1. doi: 10.1017/erm.2021.28. Expert Rev Mol Med. 2022. PMID: 34991754 Free PMC article. Review.
References
-
- Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717. - PubMed
-
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet. 1998;351:1451–1467. - PubMed
-
- Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem. 1981;256:859–868. - PubMed
-
- Lien EA, Solheim E, Lea OA, et al. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989;49:2175–2183. - PubMed
-
- Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85:151–159. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases